Epilepsy, CNS viral injury and dynorphin

Trends in Pharmacological Sciences

Volumn 25, Issue 2, 2004, Pages 98-104

  Solbrig, Marylou V ^a   Koob, George F ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b SCRIPPS RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DYNORPHIN A; MESSENGER RNA; NEUROPEPTIDE; PRODYNORPHIN;

BORNA DISEASE VIRUS; BRAIN PROTECTION; CENTRAL NERVOUS SYSTEM INFECTION; DRUG EFFECT; EPILEPSY; EPILEPTOGENESIS; GENETIC ANALYSIS; HUMAN; NERVE EXCITABILITY; NEUROMODULATION; NEUROPHARMACOLOGY; NONHUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN LOCALIZATION; REVIEW; SEIZURE; VIRUS INFECTION;

EID: 0842287907     PISSN: 01656147     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.tips.2003.12.010     Document Type: Review

References (65)

1. Engel J. Jr. A proposed diagnostic scheme for people with epileptic seizures and with epilepsy: report of the ILAE Task Force on Classification and Terminology. Epilepsia. 42:2001;796-803.
2. Wagner J.J., et al. Endogenous dynorphins inhibit excitatory neurotransmission and block LTP induction in the hippocampus. Nature. 363:1993;451-454.
3. Weisskopf M.G., et al. The opioid peptide dynorphin mediates heterosynaptic depression of hippocampal mossy fibre synapses and modulates long-term potentiation. Nature. 362:1993;423-427.
4. Terman G.W., et al. Opioid modulation of recurrent excitation in the hippocampal dentate gyrus. J. Neurosci. 20:2000;4379-4388.
5. Tortella F.C. Endogenous opioid peptides and epilepsy: quieting the seizing brain? Trends Pharmacol. Sci. 9:1988;366-372.
6. Simonato M., Romualdi P. Dynorphin and epilepsy. Prog. Neurobiol. 50:1996;557-583.
7. th Annual Scientific Meeting of the College on Problems of Drug Dependence, 1996. (Harris, L.S., ed) US Government Printing Office, National Institute on Drug Abuse Research Monograph Series 174:113.
8. Stogmann E., et al. A functional polymorphism in the prodynorphin gene promoter is associated with temporal lobe epilepsy. Ann. Neurol. 51:2002;260-263.
9. Chavkin C., et al. Dynorphin is a specific endogenous ligand of the k opioid receptor. Science. 215:1982;413-415.
10. Heriksen S.J., et al. Opioid peptides in the hippocampus: anatomical and physiological considerations. Ann. New York Acad. Sci. 398:1982;207-220.
11. Gannon R.L., Terrian D.M. U-50,488H inhibits dynorphin and glutamate release from guinea pig hippocampal mossy fiber terminal. Brain Res. 548:1991;242-247.
12. Simmons M.L., et al. Inhibition of glutamate release by presynaptic kappa 1 opioid receptors in the guinea pig dentate gyrus. J. Neurophysiol. 72:1994;1697-1705.
13. Mansour A., et al. k1 receptor mRNA distribution in the rat CNS: comparison to k receptor binding and prodynorphin mRNA. Mol. Cell. Neurosci. 5:1994;124-144.
14. McGinty J.F., et al. Dynorphin is contained within hippocampal mossy fibers: immunochemical alterations after kainic acid administration and colchicine-induced neurotoxicity. Proc. Natl. Acad. Sci. U. S. A. 80:1983;589-593.
15. Chavkin C., et al. Characterization of the prodynorphin and proenkephalin neuropeptide systems in rat hippocampus. J. Neurosci. 5:1985;808-816.
16. Gall C., et al. Cholecystokinin in the mouse hippocampus: localization in the mossy fiber and dentate commissural systems. Exp. Brain Res. 62:1986;431-437.
17. McLean S., et al. Distribution of opiate receptor subtypes and enkephalin and dynorphin immunoreactivity in the hippocampus of squirrel, guinea pig, rat, and hamster. J. Comp. Neurol. 255:1987;497-510.
18. Drake C.T., et al. Dynorphin opioids present in dentate granule cells may function as retrograde inhibitory neurotransmitters. J. Neurosci. 14:1994;3736-3750.
19. Drake C.T., et al. Kappa opioid receptor-like immunoreactivity in guinea pig brain: ultrastructural localization in presynaptic terminals in hippocampal formation. J. Comp. Neurol. 370:1996;377-395.
20. Tempel A., Zukin R.S. Neuroanatomical patterns of the mu, delta, and kappa opioid receptors of rat brain as determined by quantitative in vitro autoradiography. Proc. Natl. Acad. Sci. U. S. A. 84:1987;4308-4312.
21. Zukin R.S., et al. Characterization and visualization of rat and guinea pig brain k opioid receptors: Evidence for k1 and k2 opioid receptors. Proc. Natl. Acad. Sci. U. S. A. 85:1988;4061-4065.
22. Castillo P.E., et al. Characterizing the site and mode of action of dynorphin at hippocampal mossy fiber synapses in the guinea pig. J. Neurosci. 16:1996;5942-5950.
23. Arvidsson U., et al. The kappa-opioid receptor is primarily post-synaptic: combined immunohistochemical localization of the receptor and endogenous opioids. Proc. Natl. Acad. Sci. U. S. A. 92:1995;5062-5066.
24. Drake C.T., et al. Kappa opioid receptor-like immunoreactivity is present in substance P-containing subcortical afferents in guinea pig dentate gyrus. Hippocampus. 7:1997;36-47.
25. Halasy K., et al. Kappa opioid receptors are expressed by interneurons in the CA1 area of the rat hippocampus: a correlated light and electron microscopic immunocytochemical study. J. Chem. Neuroanat. 19:2000;233-241.
26. Racz B., Halasy K. Kappa opioid receptor is expressed by somatostatin- and neuropeptide Y-containing interneurons in the rat hippocampus. Brain Res. 931:2002;50-55.
27. Wagner J.J., et al. k-opioids decrease excitatory transmission in the dentate gyrus of the guinea pig hippocampus. J. Neurosci. 12:1992;132-141.
28. Bausch S.B., et al. Administration and endogenously released kappa opioids decrease pilocarpine-induced seizures and seizure-induced histopathology. J. Pharmacol. Exp. Ther. 284:1998;1147-1155.
29. 2+ currents and secretion in isolated neuroendocrine nerve terminal. J. Neurosci. 17:1997;6565-6574.
30. Moore S.D., et al. Voltage-dependent effects of opioid peptides on hippocampal CA3 pyramidal neurons in vitro. J. Neurosci. 14:1994;809-820.
31. Madamba S.G., et al. Dynorphin selectively augments the M-current in hippocampal CA1 neurons by an opiate receptor mechanism. J. Neurophysiol. 82:1999;1768-1775.
32. Gall C., et al. Ontogeny of enkephalin-like immunoreactivity in the rat hippocampus. Neuroscience. 11:1984;359-380.
33. Aradi I., et al. Postsynaptic effects of GABAergic synaptic diversity: regulation of neuronal excitability by changes in IPSC variance. Neuropharmacology. 43:2002;511-522.
34. Kanamatsu T., et al. Kainic acid alters the metabolism of Met5-Enkephalin and the level of dynorphin A in the rat hippocampus. J. Neurosci. 6:1986;3094-3102.
35. Douglass J., et al. Systemic administration of kainic acid differentially regulates the levels of prodynorphin and proenkephalin mRNA and peptides in the rat hippocampus. Brain Res. Mol. Brain Res. 9:1991;79-86.
36. Xie C.W., et al. Single and repeated electroconvulsive shocks alter the levels of prodynorphin and proenkephalin mRNAs in rat brain. Brain Res. Mol. Brain Res. 6:1989;11-19.
37. Romualdi P., et al. Early changes in prodynorphin mRNA and ir-dynorphin A levels after kindled seizures in the rat. Eur. J. Neurosci. 7:1995;1850-1856.
38. Rocha L., Maidment N.T. Opioid peptide release in the rat hippocampus after kainic acid-induced status epilepticus. Hippocampus. 13:2003;472-480.
39. Buckmaster P.S., Dudek F.E. Neuron loss, granule cell axon reorganization, and functional changes in the dentate gyrus of epileptic kainate-treated rats. J. Comp. Neurol. 385:1997;385-404.
40. Pierce J.P., et al. Morphometry of a peptidergic transmitter system: dynorphin B-like immunoreactivity in the rat hippocampal mossy fiber pathway before and after seizures. Hippocampus. 9:1999;255-276.
41. Sutula T., et al. Synaptic and axonal remodeling of mossy fibers in the hilus and supragranular region of the dentate gyrus in kainate-treated rats. J. Comp. Neurol. 390:1998;578-594.
42. Pierce J.P., Milner T.A. Parallel increases in the synaptic and surface areas of mossy fiber terminals following seizure induction. Synapse. 39:2001;249-256.
43. 3H]U69,593 binding in the human epileptogenic hippocampus. Epilepsy Res. 28:1997;189-205.
44. Houser C.R., et al. Altered patterns of dynorphin immunoreactivity suggest mossy fiber reorganization in human hippocampal epilepsy. J. Neurosci. 10:1990;267-282.
45. Zimprich A., et al. An allelic variation in the human prodynorphin gene promoter alters stimulus-induced expression. J. Neurochem. 74:2000;472-477.
46. Tilgen N., et al. Prodynorphin gene promoter polymorphism and temporal lobe epilepsy. Ann. Neurol. 53:2003;280-281.
47. Gambardella A., et al. Prodynorphin gene promoter polymorphism and temporal lobe epilepsy. Epilepsia. 44:2003;1255-1256.
48. Narayan O., et al. Pathogenesis of Borna Disease in rats: immune-mediated viral ophthalmoencephalopathy causing blindness and behavioral abnormalities. J. Infect. Dis. 148:1983;305-315.
49. Gosztonyi G., Ludwig H. Borna Disease-neuropathology and pathogenesis. Koprowski H., Lipkin W.I. Borna Disease. 1995;39-73 Springer-Verlag, Berlin.
50. Czygan M., et al. Borna disease virus in human brains with a rare form of hippocampal degeneration but not in brains of patients with common neuropsychiatric disorders. J. Infect. Dis. 180:1999;1695-1699.
51. Solbrig M.V., et al. Tardive dyskinetic syndrome in rats infected with Borna disease virus. Neurobiol. Dis. 1:1994;111-119.
52. Solbrig M.V., et al. Naloxone-induced seizures in rats infected with Borna disease virus. Neurology. 46:1996;1170-1171.
53. Velisek L., et al. Electrical stimulation of substantia nigra pars reticulata is anticonvulsant in adult and young male rats. Exp. Neurol. 173:2002;145-152.
54. Thai L., et al. Regulation of prodynorphin gene expression in the hippocampus by glucocorticoids. Brain Res. Mol. Brain Res. 16:1992;150-157.
55. Croll S.D., et al. Regulation of neuropeptides in adult rat forebrain by neurotrophins BDNF and NGF. Eur. J. Neurosci. 6:1994;1343-1353.
56. Solbrig M.V., et al. Neurotrophic factor expression following CNS viral injury produces enhanced sensitivity to psychostimulants: potential mechanism for addiction vulnerability. J. Neurosci. 20:2000;RC104.
57. Wilson J.L., et al. Intercellular adhesion molecule-1 expression in adjuvant arthritis in rats: inhibition by kappa-opioid agonist but not by NSAID. J. Rheumatol. 25:1998;499-505.
58. Binder W., et al. Involvement of substance P in the anti-inflammatory effects of the peripherally selective kappa-opioid asimadoline and the NK1 antagonist GR205171. Eur. J. Neurosci. 11:1999;2065-2072.
59. Chavkin C., Goldstein A. Specific receptor for the opioid peptide dynorphin: structure-activity relationships. Proc. Natl. Acad. Sci. U. S. A. 78:1981;6543-6547.
60. Kong L.Y., et al. Inhibition of lipopolysaccharide-induced nitric oxide and cytokine production by ultralow concentrations of dynorphins in mixed glia cultures. J. Pharmacol. Exp. Ther. 280:1997;61-66.
61. Wei E.T., et al. Dynorphin A(6-12) analogues suppress thermal edema. Peptides. 19:1998;767-775.
62. Sharp B.M., et al. Evidence for opioid receptors on cells involved in host defense and the immune system. J. Neuroimmunol. 83:1998;45-56.
63. Guan L., et al. Both T-cells and macrophages are targets of k-opioid-induced immunosuppression. Brain Behav. Immun. 8:1994;229-240.
64. Tang Q., et al. Dynorphin A elicits an increase in intracellular calcium in cultured neurons via a non-opioid, non-NMDA mechanism. J. Neurophysiol. 83:2000;2610-2615.
65. Gall C., et al. Seizures, neuropeptide regulation, and mRNA expression in the hippocampus. Storm-Mathisen J., et al. Progress in Brain Research. 1990;371-390 Elsevier.